Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
12,301actual
Sites
852
Countries
Argentina, Australia, Austria +30
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-06-11 | actual | When the study began enrolling |
| Primary completion | 2025-07-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-25 | actual | The whole study's end, after follow-up |
| First posted | 2019-03-13 | actual | When this record first appeared on the registry |
| Results posted | 2026-06-25 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Coronary Heart Disease (CHD)
Interventions
- Drug: Evolocumab — also filed as AMG 145, Repatha
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred First
measured From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Number of Participants Who Experienced CHD Death, MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization, Whichever Occurred First
measured From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-06-12 · 2.3 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-07-18 · 843 KB · SAP_001.pdf
Publications
- PMID 38160917 — cited as background
- PMID 42183757 — linked by the registry
- PMID 42153665 — linked by the registry
- PMID 41903215 — linked by the registry
- PMID 41211925 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed